We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
SOGROYA (Novo Nordisk Pharmaceuticals Pty Ltd)
Product name
SOGROYA
Date registered
Evaluation commenced
Decision date
Approval time
200 (255 working days
Active ingredients
somapacitan
Registration type
EOI
Indication
The approved new indication is:
the replacement of endogenous growth hormone (GH) in paediatric patients aged 2 years and above with growth failure due to growth hormone deficiency (GHD).